Incidence rates for male cancers published by @pubs.acs.org. #ProstateCancer incidence spiking again? Why? Is it just an aging population? More PSA testing? Guidelines changing? @yalecancer.bsky.social

I am reposting to highlight 2 other terms we hope we can gain consensus around: ARPI (rather than ARSI, NHT etc) and Combination therapy for mHSPC (instead of doublet/triplet or treatment intensification). Please read the rationale in this short editorial. @yalecancer.bsky.social

Fascinating! “Most study participants (44-61%) could not extract basic information—including whether they have cancer—from standard prostate cancer pathology reports but [in contrast] 93% were able to understand this diagnostic information from” patient-centered pathology reports

game-changer for tailoring treatment in high-risk cases. #Oncology #ProstateCancer @oncoalert.bsky.social @oncbrothers.bsky.social @apccc.bsky.social

Precision med includes imaging to individualize care. Of 593 biopsy-naive men, 48% had (-) prostate MRIs and were followed. After 3 yrs of monitoring, clinically significant prostate cancer was detected in 4% of men with negative MRIs. Avoiding biopsies can be considered if MRI is (-)

Thanks to @yaledailynews.bsky.social for covering my journey back to Yale and @yalecancer.bsky.social to bring #precisionmedicine to the next era. yaledailynews.com/blog/2024/12...

How often is AS/WW used in int risk prostate cancer? Leapman et al @yalecancer.bsky.social report in JAMA that AS/WW use increased from 5 - 12.3% from 2010-20, most in GG1 dz. Treat high-risk disease early, but offer AS/WW for low + some int risk cancers. jamanetwork.com/journals/jam...

#ProstateCancer screening is complicated. Unfortunately, recommendations re: screening are confusing--to the population, to those at high risk, and to physicians, as well. Can we better coordinate our guidelines among major cancer organizations? jamanetwork.com/journals/jam...

⭐️Nice review @theaacr.bsky.social journal Cancer Discovery 👉🏼The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development @ptarantinomd.bsky.social bit.ly/3YZn7OK

Vaccines against COVID-19 saved over 20 million lives in the first year alone, according to a study in Lancet Infectious Diseases. Anti vaxxers conveniently ignore such stats.

Listen.

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

“.. After an hour or so of scrolling through Bluesky the other night, I felt something I haven’t felt on social media in a long time: free. “.. Free from Elon Musk, and his tedious quest to turn X into a right-wing echo chamber ..” @kevinroose.com www.nytimes.com/2024/11/22/t...

The Chemotherapy+ Foundation was founded 55 years ago to seek out new treatments for cancer patients. I am honored to Chair the Medical Advisory Council for TCF. We had our #InnovationGala at Gustavino's and awarded Roy Herbst, MD the Ezra Greenspan award, presented by Rob Winn and Katie Politi.

Words matter in medicine: for accuracy among clinicians + researchers, and for patients, to understand their disease. We propose avoiding “castration” by unifying around HSPC and coin a new phrase ARPC for “androgen deprivation resistant prostate cancer” www.sciencedirect.com/science/arti...

I think this suggests that cancer screening will continue to rely on understanding the heterogeneity of cancer and of people. At least for now.

I am excited to join this rapidly growing #medsky community! It’s time to grow a new forum for #science-driven information and communication. #prostatecancer #precisionmedicine #medicaloncology